April 21, 2022: NCHR would like to express our substantial concerns with the overall process as well as the shortcomings of the Commitment letter.
Read More »On Health Policy
NCHR Comments on the Proposed 2022 Center for Disease Control (CDC) Clinical Practice Guideline for Prescribing Opioids
April 11, 2022: We commend the CDC for their continued efforts to reduce opioid use. However, we are very concerned that the impact of the Box 1 Guideline as currently written will be very harmful to patients.
Read More »NCHR Comments on the Development of Non-Opioid Analgesics for Acute Pain
April 11, 2022. In light of the ongoing opioid epidemic, we commend FDA’s goal of fostering the development of non-addictive alternatives to opioids for managing acute pain, and thereby decreasing exposure to opioids and preventing new addiction.
Read More »NCHR Testimony by Dr. Diana Zuckerman about AMX0035 for ALS at FDA Advisory Committee
March 30, 2022. ALS is a devastating disease and all of us want better treatments to be available as soon as possible. But NCHR agrees with FDA that “The secondary endpoint results are not compelling or supportive of the primary endpoint.”
Read More »NCHR Comments On Transitional Standards for Milk, Whole Grains, and Sodium
March 24, 2022. Nutrition standards that ensure that children receive healthy food alternatives in their school meals are of utmost importance. For this reason, we agree that USDA’s proposed transition standards, which will reduce sodium and increase whole grains, are a much-needed improvement to Child Nutrition Programs.
Read More »